These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
632 related articles for article (PubMed ID: 27783279)
1. Frequency of pathogenic germline mutation in CHEK2, PALB2, MRE11, and RAD50 in patients at high risk for hereditary breast cancer. Kim H; Cho DY; Choi DH; Oh M; Shin I; Park W; Huh SJ; Nam SJ; Lee JE; Kim SW Breast Cancer Res Treat; 2017 Jan; 161(1):95-102. PubMed ID: 27783279 [TBL] [Abstract][Full Text] [Related]
2. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals. Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067 [TBL] [Abstract][Full Text] [Related]
3. Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer. Weitzel JN; Neuhausen SL; Adamson A; Tao S; Ricker C; Maoz A; Rosenblatt M; Nehoray B; Sand S; Steele L; Unzeitig G; Feldman N; Blanco AM; Hu D; Huntsman S; Castillo D; Haiman C; Slavin T; Ziv E Cancer; 2019 Aug; 125(16):2829-2836. PubMed ID: 31206626 [TBL] [Abstract][Full Text] [Related]
4. Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer. Couch FJ; Shimelis H; Hu C; Hart SN; Polley EC; Na J; Hallberg E; Moore R; Thomas A; Lilyquist J; Feng B; McFarland R; Pesaran T; Huether R; LaDuca H; Chao EC; Goldgar DE; Dolinsky JS JAMA Oncol; 2017 Sep; 3(9):1190-1196. PubMed ID: 28418444 [TBL] [Abstract][Full Text] [Related]
5. Rare key functional domain missense substitutions in MRE11A, RAD50, and NBN contribute to breast cancer susceptibility: results from a Breast Cancer Family Registry case-control mutation-screening study. Damiola F; Pertesi M; Oliver J; Le Calvez-Kelm F; Voegele C; Young EL; Robinot N; Forey N; Durand G; Vallée MP; Tao K; Roane TC; Williams GJ; Hopper JL; Southey MC; Andrulis IL; John EM; Goldgar DE; Lesueur F; Tavtigian SV Breast Cancer Res; 2014 Jun; 16(3):R58. PubMed ID: 24894818 [TBL] [Abstract][Full Text] [Related]
6. Pathologic findings in breast, fallopian tube, and ovary specimens in non-BRCA hereditary breast and/or ovarian cancer syndromes: a study of 18 patients with deleterious germline mutations in RAD51C, BARD1, BRIP1, PALB2, MUTYH, or CHEK2. Schoolmeester JK; Moyer AM; Goodenberger ML; Keeney GL; Carter JM; Bakkum-Gamez JN Hum Pathol; 2017 Dec; 70():14-26. PubMed ID: 28709830 [TBL] [Abstract][Full Text] [Related]
7. Germline mutations of PALB2 gene in a sequential series of Chinese patients with breast cancer. Zhang K; Zhou J; Zhu X; Luo M; Xu C; Yu J; Deng M; Zheng S; Chen Y Breast Cancer Res Treat; 2017 Dec; 166(3):865-873. PubMed ID: 28825143 [TBL] [Abstract][Full Text] [Related]
8. Cancer risk management among female BRCA1/2, PALB2, CHEK2, and ATM carriers. Cragun D; Weidner A; Tezak A; Clouse K; Pal T Breast Cancer Res Treat; 2020 Jul; 182(2):421-428. PubMed ID: 32445176 [TBL] [Abstract][Full Text] [Related]
9. BRCA1, BRCA2 and PALB2 mutations and CHEK2 c.1100delC in different South African ethnic groups diagnosed with premenopausal and/or triple negative breast cancer. Francies FZ; Wainstein T; De Leeneer K; Cairns A; Murdoch M; Nietz S; Cubasch H; Poppe B; Van Maerken T; Crombez B; Coene I; Kerr R; Slabbert JP; Vral A; Krause A; Baeyens A; Claes KB BMC Cancer; 2015 Nov; 15():912. PubMed ID: 26577449 [TBL] [Abstract][Full Text] [Related]
10. Frequency of pathogenic germline variants in BRCA1, BRCA2, PALB2, CHEK2 and TP53 in ductal carcinoma in situ diagnosed in women under the age of 50 years. Petridis C; Arora I; Shah V; Megalios A; Moss C; Mera A; Clifford A; Gillett C; Pinder SE; Tomlinson I; Roylance R; Simpson MA; Sawyer EJ Breast Cancer Res; 2019 May; 21(1):58. PubMed ID: 31060593 [TBL] [Abstract][Full Text] [Related]
11. PALB2 c.2257C>T truncating variant is a Greek founder and is associated with high breast cancer risk. Vagena A; Papamentzelopoulou M; Kalfakakou D; Kollia P; Papadimitriou C; Psyrri A; Apostolou P; Fountzilas G; Konstantopoulou I; Yannoukakos D; Fostira F J Hum Genet; 2019 Aug; 64(8):767-773. PubMed ID: 31089269 [TBL] [Abstract][Full Text] [Related]
12. Frequency of mutations in BRCA genes and other candidate genes in high-risk probands or probands with breast or ovarian cancer in the Czech Republic. Riedlova P; Janoutova J; Hermanova B Mol Biol Rep; 2020 Apr; 47(4):2763-2769. PubMed ID: 32180084 [TBL] [Abstract][Full Text] [Related]
13. Variants of cancer susceptibility genes in Korean BRCA1/2 mutation-negative patients with high risk for hereditary breast cancer. Park JS; Lee ST; Nam EJ; Han JW; Lee JY; Kim J; Kim TI; Park HS BMC Cancer; 2018 Jan; 18(1):83. PubMed ID: 29338689 [TBL] [Abstract][Full Text] [Related]
14. Breast cancer risk associated with genes encoding DNA repair MRN complex: a study from Punjab, Pakistan. Khan RT; Siddique A; Shahid N; Khokher S; Fatima W Breast Cancer; 2018 May; 25(3):350-355. PubMed ID: 29368209 [TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical findings and clinicopathological features of breast cancers with pathogenic germline mutations in Non-BRCA genes. Singh K; Scalia J; Legare R; Quddus MR; Sung CJ Hum Pathol; 2024 Apr; 146():49-56. PubMed ID: 38608781 [TBL] [Abstract][Full Text] [Related]
17. Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in Yadav S; Boddicker NJ; Na J; Polley EC; Hu C; Hart SN; Gnanaolivu RD; Larson N; Holtegaard S; Huang H; Dunn CA; Teras LR; Patel AV; Lacey JV; Neuhausen SL; Martinez E; Haiman C; Chen F; Ruddy KJ; Olson JE; John EM; Kurian AW; Sandler DP; O'Brien KM; Taylor JA; Weinberg CR; Anton-Culver H; Ziogas A; Zirpoli G; Goldgar DE; Palmer JR; Domchek SM; Weitzel JN; Nathanson KL; Kraft P; Couch FJ J Clin Oncol; 2023 Mar; 41(9):1703-1713. PubMed ID: 36623243 [TBL] [Abstract][Full Text] [Related]
18. Rare, protein-truncating variants in Decker B; Allen J; Luccarini C; Pooley KA; Shah M; Bolla MK; Wang Q; Ahmed S; Baynes C; Conroy DM; Brown J; Luben R; Ostrander EA; Pharoah PD; Dunning AM; Easton DF J Med Genet; 2017 Nov; 54(11):732-741. PubMed ID: 28779002 [TBL] [Abstract][Full Text] [Related]
19. Profiling of the genetic features of patients with breast, ovarian, colorectal and extracolonic cancers: Association to CHEK2 and PALB2 germline mutations. Infante M; Arranz-Ledo M; Lastra E; Olaverri A; Ferreira R; Orozco M; Hernández L; Martínez N; Durán M Clin Chim Acta; 2024 Jan; 552():117695. PubMed ID: 38061684 [TBL] [Abstract][Full Text] [Related]
20. Protein-truncating variants in moderate-risk breast cancer susceptibility genes: a meta-analysis of high-risk case-control screening studies. Aloraifi F; McCartan D; McDevitt T; Green AJ; Bracken A; Geraghty J Cancer Genet; 2015 Sep; 208(9):455-63. PubMed ID: 26250988 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]